These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1162 related articles for article (PubMed ID: 2306754)
21. Induction of murine lymphokine-activated killer cells by recombinant IL-7. Lynch DH; Miller RE J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262 [TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody. Yun YS; Hargrove ME; Ting CC J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924 [TBL] [Abstract][Full Text] [Related]
23. Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG. MacDougall JR; Croy BA; Chapeau C; Clark DA Cell Immunol; 1990 Oct; 130(1):106-17. PubMed ID: 2144467 [TBL] [Abstract][Full Text] [Related]
24. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432. Shimoda K; Saito T; Kobayashi M; Nomoto K Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903 [TBL] [Abstract][Full Text] [Related]
25. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations. Ballas ZK; Rasmussen W; van Otegham JK J Immunol; 1987 Mar; 138(5):1647-52. PubMed ID: 2879870 [TBL] [Abstract][Full Text] [Related]
27. Heterogeneity of cell surface structures involved in cytotoxicity mediated by lymphokine activated killer cells. Bean P; Agah R; Mazumder A J Biol Response Mod; 1990 Feb; 9(1):92-7. PubMed ID: 2181073 [TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Vujanovic NL; Herberman RB; Hiserodt JC Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411 [TBL] [Abstract][Full Text] [Related]
29. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
30. Effect of macrophages on interleukin-2 (IL-2)- and IL-4-induced murine lymphokine-activated killer activity. Tunru IS; Suzuki H; Yano S Int J Cancer; 1991 Jun; 48(4):568-73. PubMed ID: 2045201 [TBL] [Abstract][Full Text] [Related]
31. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526 [TBL] [Abstract][Full Text] [Related]
32. Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells. Chen MF; Suzuki H; Yano S Anticancer Res; 1992; 12(2):451-6. PubMed ID: 1580562 [TBL] [Abstract][Full Text] [Related]
33. MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies. Sarin A; Haridas V; Saxena RK Immunol Lett; 1993 Sep; 38(1):59-62. PubMed ID: 8300155 [TBL] [Abstract][Full Text] [Related]
34. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774 [TBL] [Abstract][Full Text] [Related]
35. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states. Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654 [TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer (LAK) activity to cultured rat kidney parenchymal components in vitro. Nietosvaara Y; Renkonen R; Mattila P; Häyry P Transpl Int; 1989 Dec; 2(4):209-13. PubMed ID: 2627263 [TBL] [Abstract][Full Text] [Related]
37. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. Yang JC; Mulé JJ; Rosenberg SA J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187 [TBL] [Abstract][Full Text] [Related]
38. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors. Miller JS; Verfaillie C; McGlave P Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991 [TBL] [Abstract][Full Text] [Related]
39. Lysis of murine macrophages by lymphokine-activated killer-like cells induced by BCG in vitro. Chen MF; Suzuki H; Yano S Microbiol Immunol; 1991; 35(7):557-67. PubMed ID: 1784257 [TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]